Asche Carl V, Ren Jinma, Kim Minchul, Gordon Kate, McWhirter Marie, Kirkness Carmen S, Maurer Brian T
a Center for Outcomes Research, University of Illinois College of Medicine at Peoria , Peoria , IL , USA.
b Department of Pharmacy Systems, Outcomes & Policy , University of Illinois at Chicago College of Pharmacy , Chicago , IL , USA.
Curr Med Res Opin. 2017 Jul;33(7):1283-1290. doi: 10.1080/03007995.2017.1314262. Epub 2017 Apr 28.
To assess postsurgical clinical and economic outcomes of patients who received local infiltration containing liposomal bupivacaine versus traditional bupivacaine for pain management following total hip arthroplasty (THA).
This retrospective study included two groups of consecutive patients undergoing THA. The experimental group received local infiltration with a combination of liposomal bupivacaine, bupivacaine HCl 0.25% with epinephrine 1:200,000, and ketorolac for postsurgical analgesia. The historical control group received the previous standard of care: local infiltration with a combination of bupivacaine HCl 0.25% with epinephrine 1:200,000 and ketorolac. Key outcomes included distance walked, length of stay (LOS), opioid medication use, numeric pain scores, hospital charges, hospital costs, all-cause 30 day readmission rate, and adverse events (AEs). Both unadjusted and adjusted (i.e. age, sex, insurance type, living situation, body mass index, procedure side, and comorbidity) outcomes were compared between the two groups.
The experimental group (n = 64) demonstrated statistically significant improvement versus the historical control group (n = 66) in mean distance walked on discharge day (249.2 vs. 180.0 feet; unadjusted p = .025, adjusted p = .070), mean LOS (2.0 vs. 2.7 days; p < .001, p = .002), proportion of patients who used opioid rescue medication on postoperative day (POD) 1 (29.7% vs. 56.1%; p = .002, p = .003) and POD 2 (7.8% vs. 30.3%; p = .001, p = .003), mean cumulative area under the curve for pain score on POD 0 (127.6 vs. 292.5; p < .001, both), POD 1 (92.9 vs. 185.0; p < .001, both), and POD 2 (93.8 vs. 213.8; p = .006, both). Among a subgroup of patients with available financial information, mean hospital charges were lower in the experimental group ($43,794 [n = 24] vs. $48,010 [n = 66]; p < .001, both). Rates of all-cause 30 day readmission and AEs were not significantly different between groups. No falls occurred.
Infiltration at the surgical site with liposomal bupivacaine was associated with improved postsurgical outcomes when compared with traditional bupivacaine in patients undergoing THA.
评估全髋关节置换术(THA)后接受含脂质体布比卡因的局部浸润麻醉与传统布比卡因进行疼痛管理的患者的术后临床和经济结局。
这项回顾性研究纳入了两组连续接受THA的患者。实验组接受脂质体布比卡因、0.25%盐酸布比卡因与1:200,000肾上腺素以及酮咯酸联合进行局部浸润麻醉以用于术后镇痛。历史对照组接受先前的标准治疗:0.25%盐酸布比卡因与1:200,000肾上腺素以及酮咯酸联合进行局部浸润麻醉。关键结局包括行走距离、住院时间(LOS)、阿片类药物使用情况、数字疼痛评分、医院收费、医院成本、30天全因再入院率以及不良事件(AE)。对两组的未调整结局和调整结局(即年龄、性别、保险类型、生活状况、体重指数、手术侧以及合并症)进行比较。
实验组(n = 64)与历史对照组(n = 66)相比,在出院日的平均行走距离(249.2对180.0英尺;未调整p = 0.025,调整p = 0.070)、平均住院时间(2.0对2.7天;p < 0.001,p = 0.002)、术后第1天(POD 1)使用阿片类急救药物的患者比例(29.7%对56.1%;p = 0.002,p = 0.003)和POD 2(7.8%对30.3%;p = 0.001,p = 0.003)、POD 0时疼痛评分的平均曲线下累积面积(127.6对292.5;p < 0.001,两者均是)、POD 1(92.9对185.0;p < 0.001,两者均是)以及POD 2(93.8对213.8;p = 0.006,两者均是)方面显示出统计学上的显著改善。在有可用财务信息的患者亚组中,实验组的平均医院收费更低(43,794美元[n = 24]对48,010美元[n = 66];p < 0.001,两者均是)。两组间的30天全因再入院率和AE发生率无显著差异。未发生跌倒事件。
与传统布比卡因相比,接受THA的患者在手术部位使用脂质体布比卡因浸润麻醉与更好的术后结局相关。